Matthew M. Riggs, Ph.D.

Chief Science Officer

Matt offers over 16 years of industry experience including the application of modeling and simulation for clinical pharmacology and later phase drug development decisions. Matt’s interests include the development and application of mechanistic exposure-response and systems pharmacology models to quantitatively integrate physiology, pharmacology, senescence and disease understandings; this to guide translational and clinical research toward improved preventative and interventional therapeutics.

Recent publications by this scientist

Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda

November 14, 2022

Katherine Kay, Justin Goodwin, Hanna Ehrlich, Joyce Ou, Tracey Freeman, Kaicheng Wang, Fangyong Li, Martina Wade, Jonathan French, Liusheng Huang, Francesca Aweeka, Norah Mwebaza, Richard Kajubi, Matthew Riggs, Ana Ruiz-Garcia, Sunil Parikh. Clin Pharmacol Ther. Published online October 19, 2022. doi:10.1002/cpt.2768

Download PDF

View More

Association of lumefantrine pharmacokinetics and resistance selection following artemether-lumefantrine treatment in children with and without HIV in Uganda

November 10, 2022

Katherine Kay, Justin Goodwin, Hanna Ehrlich, Joyce Ou, Tracy Freeman, Kaicheng Wang, Fangyong Li, Martina Wade, Jonathan French, Liusheng Huang, Francesca T. Aweeka, Norah Mwebaza, Richard Kajubi, Matthew Riggs, Ana Ruiz-Garcia, Sunil Parikh. Poster presented at American Society of Tropical Medicine and Hygiene (ASTMH). October 30 – November 3, 2022. Poster #1434.

Download PDF

A showcase of open-source tools for scalable, reproducible PMx workflows

October 31, 2022

Kyle Baron, Sam Callisto, Seth Green, Matthew Riggs. A showcase of open-source tools for scalable, reproducible PMx workflows. Pre Meeting Workshop presented at 2022 American Conference on Pharmacometrics (ACoP13). 30 October 2022.

Download PDF